NCT01041404 arm group e52e64863ebfd564a746193cedad898c [clinicaltrials_resource:NCT01041404/arm-group/e52e64863ebfd564a746193cedad898c]
Cisplatin [clinicaltrials_resource:819f49fe8737385a2fe80a8096009b29]Trastuzumab [clinicaltrials_resource:c42f2b9f3d7fe72b467e7a26d088e801]Capecitabine [clinicaltrials_resource:e857e886c3d6157e16185033c69e97cc]Fluorouracil [clinicaltrials_resource:eaa2a8b1e7271bdadb1cdb583f02e443]clinicaltrials:NCT01041404
arm group [clinicaltrials_vocabulary:arm-group]
NCT01041404 arm group e52e64863ebfd564a746193cedad898c [clinicaltrials_resource:NCT01041404/arm-group/e52e64863ebfd564a746193cedad898c]
Bio2RDF identifier
NCT01041404/arm-group/e52e64863ebfd564a746193cedad898c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 2e64863ebfd564a746193cedad898c
description [clinicaltrials_vocabulary:description]
Participants received an initi ...... le every 3 weeks for 6 cycles.
identifier
clinicaltrials_resource:NCT01041404/arm-group/e52e64863ebfd564a746193cedad898c
title
NCT01041404 arm group e52e64863ebfd564a746193cedad898c
@en
type
label
NCT01041404 arm group e52e6486 ...... e64863ebfd564a746193cedad898c]
@en